Quantcast

Latest pharmaceutical industry Stories

2014-08-14 16:27:42

Pharmacy benefit manager misleading patients, advocates say FAIRHOPE, Ala., Aug. 14, 2014 /PRNewswire/ -- Express Scripts, the nation's largest pharmacy benefit manager, is offering ambiguous and misleading reasons for ending coverage of customized prescription medications for 540,000 individuals in order to conceal financial motives, a Patients and Physicians for Rx Access said Thursday, Aug. 14. The organization is fighting to stop the unprecedented benefit cuts being made by...

2014-08-14 08:30:05

First Patient Dosed in the EU Post-Authorization Safety Study MOUNTAIN VIEW, Calif., Aug. 14, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE(®) inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies: -- a benzodiazepine interaction study - study completed and data...

2014-08-14 08:29:19

SAN DIEGO, Aug. 14, 2014 /PRNewswire/ -- Formex, LLC ("Formex"), a leader in pharmaceutical development and manufacturing, announced that Mr. John McCarty has joined Formex as Scientific Advisor and Science Advisory Board Member. Mr. McCarty has over 30 years of experience in drug product development within the pharmaceutical and biotechnology industries. Mr. McCarty has broad expertise in the development of all major dosage forms and is an inventor on over 17 U.S. and foreign...

2014-08-14 08:28:23

-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 -- ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three and six months ended June 30, 2014, and provided an operational...

2014-08-13 23:08:14

The Aug. 8 issue of Atlantic Information Services’s Drug Benefit News (DBN) takes a look at criticism surrounding formulary exclusion lists, which pharmacy benefit managers see as a way to flex their negotiating muscle and control rising drug trend. Washington, DC (PRWEB) August 13, 2014 In a continuing effort to flex their negotiating muscle and control rising drug trend, CVS Caremark Corp. and Express Scripts Holding Co. on Aug. 1 released their respective long-awaited formulary...

2014-08-13 23:03:42

Researchmoz.us announces addition of new report "Neuropathy Global Clinical Trials Review, H2, 2014" to its database. Albany, NY (PRWEB) August 13, 2014 "Clinical trial report, Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the...

2014-08-13 16:26:30

TORONTO, Aug. 13, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and six months ended June 30, 2014. All financial references are in U.S. dollars unless otherwise noted. Financial Results...

2014-08-13 16:25:38

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis(®) (carfilzomib) for Injection...

2014-08-13 16:25:21

ReportsnReports.com offer Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges a market research report added to its store. DALLAS, Aug. 13, 2014 /PRNewswire-iReach/ -- The report on Pharmaceutical Industry in China provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government...

2014-08-13 08:29:58

Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected. BETHESDA, Md., Aug. 13, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today corrected ongoing false claims by Adam Feuerstein published on the TheStreet.com about the Company's Phase III trial of DCVax-L...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related